浏览全部资源
扫码关注微信
CD151通过上皮间质转化及干性相关通路调控非小细胞肺癌脑转移的机制研究
CD151 inhibits brain metastasis of non-small cell lung cancer by regulating epithelial-mesenchymal transition and stemness pathways
- 第三军医大学学报 2018年40卷第10期 页码：862-867
- 作者机构：
400042 重庆，陆军军医大学(第三军医大学)第三附属医院(野战外科研究所)肿瘤中心
- 作者简介：
[ 杨镇洲, E-mail: yangzhenzhou@sohu.com YANG Zhenzhou, E-mail: yangzhenzhou@sohu.com
- 基金信息：重庆市基础科学与前沿技术研究重点项目(CSTC2015jcyjBX0084)
DOI：10.16016/j.1000-5404.201712264
中图分类号： R73.37;R730.23;R734.2收稿：2017-12-27，
修回：2018-02-21，
纸质出版：2018-05-30
- 稿件说明：
移动端阅览
王帅, 张诗珩, 张志敏, 等. CD151通过上皮间质转化及干性相关通路调控非小细胞肺癌脑转移的机制研究[J]. 第三军医大学学报, 2018,40(10):862-867.
Shuai WANG, Shiheng ZHANG, Zhimin ZHANG, et al. CD151 inhibits brain metastasis of non-small cell lung cancer by regulating epithelial-mesenchymal transition and stemness pathways[J]. Journal of Third Military Medical University, 2018, 40(10): 862-867.
王帅, 张诗珩, 张志敏, 等. CD151通过上皮间质转化及干性相关通路调控非小细胞肺癌脑转移的机制研究[J]. 第三军医大学学报, 2018,40(10):862-867. DOI： 10.16016/j.1000-5404.201712264.
Shuai WANG, Shiheng ZHANG, Zhimin ZHANG, et al. CD151 inhibits brain metastasis of non-small cell lung cancer by regulating epithelial-mesenchymal transition and stemness pathways[J]. Journal of Third Military Medical University, 2018, 40(10): 862-867. DOI： 10.16016/j.1000-5404.201712264.
摘要
目的
2
探讨四跨膜蛋白CD151在肺癌脑转移中的预测作用及相关分子通路机制。
方法
2
收集2010年12月至2015年6月本中心160例非小细胞肺癌(non-small cell lung cancer
NSCLC)患者临床资料，其中脑转移患者88例，无脑转移患者72例，采用免疫组织化学方法检测CD151在肺癌组织的表达，并运用Spearman分析CD151表达与脑转移相关性。再选择人NSCLC细胞株HCC827，应用siRNA干扰、Western blot、划痕和Transwell实验检测敲低CD151表达对细胞增殖、迁移状况以及上皮间质转化(EMT)、干性通路相关蛋白表达的影响。
结果
2
相对于无脑转移患者，NSCLC脑转移患者肺癌组织CD151表达显著增加(
P
=0.012)，Spearman分析表明CD151高表达与脑转移呈正相关(
r
=0.478
P
=0.004)。通过siRNA敲低CD151可上调Ecadherin表达，并下调Vimentin、SOX2、CD44和CD133表达，同时降低HCC827细胞增殖(
P
=0.026)与迁移能力(
P
=0.032)。
结论
2
CD151可能通过调控EMT、干性通路相关蛋白表达影响NSCLC细胞的增殖、迁移，CD151可能是NSCLC脑转移的潜在预测因子。
Abstract
Objective
2
To investigate the value of CD151 for predicting brain metastasis of lung cancer and explore its role in promoting lung cancer metastasis and the associated signaling pathways.
Methods
2
A total of 160 patients with non-small cell lung cancer (NSCLC) admitted in our center between December
2010 and June
2015 were enrolled in this study
including 88 patients with and 72 without brain metastases. CD151 expression in the lung cancer tissues was examined using immunohistochemistry and its correlation with brain metastasis was analyzed. In the
in vitro
experiment with human NS
CLC cell line (HCC827 cells)
RNA interference technique
scratch-wound assay
Transwell assay and Western blotting were used to clarify the role of CD151 in regulating cell proliferation
migration
epithelial-mesenchymal transition
and expressions of proteins in the stemness pathways.
Results
2
Compared with those without brain metastasis
the patients with brain metastasis of NSCLC showed significantly up-regulated CD151 expression in the lung cancer tissues (
P
=0.012). Spearman correlation analysis showed that a high expression of CD151 was positively correlated with brain metastasis of NSCLC (
r
=0.478
P
=0.004). HCC827 cells with CD151 knockdown mediated by a small interfering RNA showed obviously suppressed cell proliferation (
P
=0.026) and metastasis (
P
=0.032)
up-regulated expression of E-cadherin and down-regulated expression of vimentin
SOX2
CD44 and CD133.
Conclusion
2
CD151 promotes the proliferation and migration of NSCLC cells possibly by regulating the protein expression associated with epithelial-mesenchymal transition and stemness pathways
suggesting its value as a potential biomarker for predicting brain metastases of lung cancer.
关键词
Keywords
references
CHEN W, ZHENG R, BAADE P D. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
JEMAL A, CENTER M M, DESANTISC. Global patterns of cancer incidence and mortality rates and trends[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19(8): 1893-1907. DOI: 10.1158/1055-9965.
BROWN T, PILKINGTON G, BAGUST A, et al . Clinical effectiveness and cost-effectiveness of fi rst-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation[J ] . Health Technol Assess, 2013, 17(31): 1-278. DOI: 10.3310/hta17310.
SPIRO S G, TANNER N T, SILVESTRI G A, et al .Lungcancer: progress in diagnosis, staging andtherapy[J ] . Respirology, 2010, 15(1): 44-50. DOI: 10.1111/j.1440-1843.2009.01674.x.
KAWAHARA M, ATAGI S, KOMUTA K, et al . Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced non-small cell lung cancer[J ] . Anticancer Res, 2013, 33(10): 4631-4637. DOI: 0.1371/journal.pone.0111475.
TATAR Z, THIVAT E, PLANCHAT E, et al . Temozolomide and unusual indications: review of literature[J ] . Cancer Treat Rev, 2013, 39(2): 125-135. DOI: 10.1016/j.ctrv.2012.06.002.
LIU WJ, ZENG XT, QIN HF, et al . Whole brain radiotherapy plus chemotherapy in the treatment of brain metastases from lung cancer: a meta-analysis of 19 randomized controlled trails[J ] . Asian Pac J Cancer Prev, 2012, 13(7): 3253-3258. DOI: 10.7314/APJCP.2012.13.7.3253.
WANG H X, LIQ, SHARMAC, et al . Tetraspanin protein contributions to cancer[J ] . Biochem Soc Trans, 2011, 39(2): 547-552. DOI: 10.1042/BST0390547.
GHELDOF A, BERX G. Cadherins and epithelial-to-mesenchymaltransition[J]. Prog Mol Biol Transl Sci. 2013, 116: 317-336. DOI: 10.1016/B978-0-12-394311-8.00014-5.
THIERY J P, ACLOQUE H, HUANG RY J, et al . Epithelial-mesenchymal transitions in development and disease[J ] . Cell, 2009, 139(5): 871-890. DOI: 10.1016/j.cell.2009.11.007.
MEDEMA J P. Cancer stem cells: the challenges ahead[J]. Nat Cell Biol, 2013, 15(4): 338-344. DOI: 10.1038/ncb2717.
李科, 洪志鹏, 沈丽达, 等. CD151及整合素α整合素蛋白在非小细胞肺癌中的表达及意义[J].中国全科医学, 2014, 17(5): 531-535. DOI: 10.3969/j.issn.1007-9572.
LI K, HONG Z P, SHEN L D, et al . CD151 and integrin α3β1 expression in non-small cell lung cancer[J ] . Chin Gen Prac, 2014, 17(5): 531-535. DOI: 10.3969/j.issn.1007-9572.
0
浏览量
0
下载量
0
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
